PBM Capital Group is a private investment firm primarily focused on healthcare investments.
Business Model:
Revenue: $17.4M
Employees: 11-50
Address: 200 Garrett St
City: Charlottesville
State: VA
Zip: 22902
Country: US
PBM Capital Group, LLC. is a private investment firm primarily focused on healthcare investments. Led by Paul Manning, a successful entrepreneur, it invests across all stages of corporate development– including venture capital, leveraged buyouts, growth capital, distressed/turnaround, and public equity value investing– and create value by applying extensive industry knowledge and contacts, providing superior operational expertise and bringing an entrepreneurial spirit to attractive investment opportunities. We actively partner with our portfolio companies to drive commercial success and enhance profitability.
Contact Phone:
+14349808100
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2019 | ArcherDX | Series B | 60M |
9/2021 | LEXEO Therapeutics | Series B | 0 |
8/2019 | Landos Biopharma | Series B | 60M |
8/2021 | Xalud Therapeutics | Series C | 0 |
2/2021 | PatientsLikeMe | Venture Round | 0 |
4/2020 | Atsena Therapeutics | Venture Round | 8.2M |
1/2019 | Candel Therapeutics | Series B | 28.7M |
5/2021 | Genapsys | Series D | 0 |
2/2021 | SalioGen Therapeutics | Series A | 0 |
12/2019 | ArcherDX | Series C | 0 |
10/2018 | Acumen Pharmaceuticals | Series A | 15M |
1/2021 | LEXEO Therapeutics | Series A | 0 |
3/2018 | ArcherDX | Series A | 35M |
9/2018 | Nanoview Biosciences | Series B | 10M |
7/2020 | Verona Pharma | Private Placement | 200M |
4/2020 | Taysha Gene Therapies | Seed Round | 0 |
11/2020 | Acumen Pharmaceuticals | Series B | 0 |
8/2020 | Taysha Gene Therapies | Series B | 0 |
9/2021 | LEXEO Therapeutics | Series B | 0 |
8/2021 | Xalud Therapeutics | Series C | 0 |
5/2021 | Genapsys | Series D | 0 |
2/2021 | SalioGen Therapeutics | Series A | 0 |
2/2021 | PatientsLikeMe | Venture Round | 0 |
1/2021 | LEXEO Therapeutics | Series A | 0 |
11/2020 | Acumen Pharmaceuticals | Series B | 0 |
8/2020 | Taysha Gene Therapies | Series B | 0 |
7/2020 | Verona Pharma | Post-IPO Equity | 0 |
4/2020 | Taysha Gene Therapies | Seed Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|